Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Ceeto Capital Group LLC

Ceeto Capital Group LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 16,200 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the quarter. Ceeto Capital Group LLC’s holdings in Gilead Sciences were worth $1,187,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences in the 4th quarter valued at $29,000. Sachetta LLC acquired a new position in Gilead Sciences in the 4th quarter valued at $30,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences in the 1st quarter valued at $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at $33,000. Finally, Gladius Capital Management LP acquired a new position in Gilead Sciences in the 4th quarter valued at $34,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday, July 8th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. UBS Group lowered their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Hold” and a consensus target price of $81.81.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.7 %

Shares of NASDAQ GILD traded up $0.50 on Friday, reaching $77.01. 7,453,639 shares of the company traded hands, compared to its average volume of 6,033,727. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a 50 day moving average of $67.79 and a 200 day moving average of $70.98. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $95.94 billion, a PE ratio of 213.92, a P/E/G ratio of 3.28 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the prior year, the company posted $1.37 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.